A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2018
Price : $35 *
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Cystinosis
- Focus Therapeutic Use
- Sponsors Raptor Pharmaceutical Inc
- 26 Jul 2017 Status changed from active, no longer recruiting to completed.
- 14 Jul 2017 Results published in the Horizon Pharma plc media release.
- 14 Jul 2017 According to a Horizon Pharma plc media release, the company presented result of Halitosis Substudy (n=20) at the Cystinosis Research Network (CRN) 2017 Family Conference.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History